28.1 C
Delhi
Wednesday, October 9, 2024

Tag: Takeda

Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies

Business Wire India  LIVTENCITY Is the First and Only Inhibitor of CMV-specific UL97 Protein Kinase Approved in China for the Treatment of Adults With Post-transplant...

Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners

Business Wire India ​2024 Award Celebrates Outstanding Research in Cancer Immunology Winners Discovered Novel Connections Between the Immune System and Cancer Recipients Each Receive...

- A word from our sponsors -

spot_img

Follow us

HomeTagsTakeda